OnKure Therapeutics (OKUR) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
25 Nov, 2025Opening remarks and agenda
Meeting called to order by the Chair, with introductions of directors and officers in attendance.
Agenda included election of two Class 1 directors and ratification of the independent auditor.
Corporate governance
Notice of proxy materials was sent to shareholders of record, and a quorum was confirmed.
Inspector of Elections appointed and sworn in to oversee voting.
Overview of voting outcomes
Isaac Mankey and Nicholas Saccomano elected as Class 1 directors to serve until the 2028 annual meeting.
KPMG ratified as independent registered public accounting firm for the fiscal year ending December 31, 2025.
Voting conducted by proxy and online ballot, with polls open and closed during the meeting.
Preliminary results announced, with final results to be filed with the SEC on Form 8-K.
Latest events from OnKure Therapeutics
- Key clinical milestones and a strong cash position highlight progress in PI3Ka-targeted therapies.OKUR
Q4 202512 Mar 2026 - OKI-219 demonstrates high selectivity and tolerability, with key data expected later this year.OKUR
Leerink's Global Healthcare Conference 202526 Dec 2025 - Q1 2026 will bring pivotal OKI-219 data, driving expansion in triplet and pan-mutant programs.OKUR
Evercore ISI 8th Annual HealthCONx Conference13 Dec 2025 - OKI-219 demonstrates high selectivity and tolerability, with key combination trials ongoing.OKUR
Stifel 2025 Virtual Targeted Oncology Forum25 Nov 2025 - OKI-219 shows high selectivity and tolerability, with pivotal data expected in Q1 2026.OKUR
Guggenheim Securities 2nd Annual Healthcare Innovation Conference17 Nov 2025 - OKI-219 shows strong selectivity and safety, with pivotal breast cancer trial data expected in Q1 2026.OKUR
Stifel 2025 Healthcare Conference17 Nov 2025 - OKI-219 shows promise as a selective PI3Kα inhibitor in breast cancer, with key data due Q1 2026.OKUR
Investor Presentation14 Nov 2025 - Advanced clinical programs and strong cash position set stage for key data in early 2026.OKUR
Q3 20256 Nov 2025 - Q1 2025 net loss was $15.9M, cash $96.7M, and cash runway extends into Q4 2026.OKUR
Q1 20258 Oct 2025